Filing Details
- Accession Number:
- 0001225208-13-024118
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2013-11-22 16:04:01
- Reporting Period:
- 2013-11-20
- Filing Date:
- 2013-11-22
- Accepted Time:
- 2013-11-22 16:04:01
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1385187 | Covidien Plc | COV | Surgical & Medical Instruments & Apparatus (3841) | 980624794 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1335303 | L Peter Wehrly | C/O Covidien 15 Hampshire Street Mansfield MA 02048 | Senior Vice President | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Ordinary Shares | Acquisiton | 2013-11-20 | 20,998 | $0.00 | 50,927 | No | 4 | A | Direct | |
Ordinary Shares | Disposition | 2013-11-20 | 9,913 | $66.37 | 41,014 | No | 4 | F | Direct | |
Ordinary Shares | Acquisiton | 2013-11-22 | 4,409 | $29.53 | 45,423 | No | 4 | M | Direct | |
Ordinary Shares | Disposition | 2013-11-22 | 4,409 | $66.82 | 41,014 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | A | Direct | |
No | 4 | F | Direct | |
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Ordinary Shares | Stock Option (Right to Buy) | Disposition | 2013-11-22 | 4,409 | $0.00 | 4,409 | $29.53 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | 2019-04-30 | No | 4 | M | Direct |
Footnotes
- Reflects ordinary shares acquired upon vesting of performance share units.
- The price reported is the weighted average price. Shares were sold in multiple transactions at prices ranging from $66.8209 to $66.8220. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a securityholder of the Issuer, full information regarding the number of shares sold at each price.
- Adjusted in connection with the spin-off of Covidien's pharmaceuticals business.
- Options became exercisable in equal installments on each of the first, second, third and fourth anniversary of the grant date.